Pop C Florin, Ortega Clémence, Lecomte Mathilde, Kristanto Paulus, Khaled Chirine, De Neubourg Filip, Desmet Antoine, De Azambuja Evandro, Larsimont Denis, Veys Isabelle
Department of Surgical Oncology, Breast Clinic, Institut Jules Bordet, The Brussels University Hospital (HUB), Université Libre de Bruxelles, Brussels, Belgium.
Data Centre and Statistics Department, Institut Jules Bordet, The Brussels University Hospital (HUB), Université Libre de Bruxelles, Brussels, Belgium.
NPJ Breast Cancer. 2025 May 19;11(1):45. doi: 10.1038/s41523-025-00756-5.
Current evidence does not support the application of "no-ink-on-tumor" negative margins following breast-conserving surgery (BCS) in breast cancer (BC) patients who have received neoadjuvant systemic treatment (NST). We compared loco-regional free survival (LRFS), disease-free survival (DFS), and overall survival (OS) based on different tumor margin distance thresholds in a cohort of 235 BC patients treated with NST and subsequent BCS between 01/2015 and 12/2019. The 5-year LRFS was 81.6% in patients with "no-ink-on-tumour", margins and 71.0% in those with positive margins (p = 0.584). Margins >1 mm were associated with superior outcomes, with a 5-year LRFS of 84.0% compared to 69.3% in patients with margins ≤1 mm (p = 0.005). Additionally, margins >1 mm were significantly correlated with longer DFS (p = 0.028) and OS (p = 0.001). These findings suggest that a surgical margin distance >1 mm provides the best LRFS, DFS, and OS outcomes for this group of BC patients.
目前的证据并不支持在接受新辅助全身治疗(NST)的乳腺癌(BC)患者中,保乳手术(BCS)后应用“肿瘤无墨水”阴性切缘。我们在2015年1月至2019年12月期间接受NST及后续BCS治疗的235例BC患者队列中,根据不同的肿瘤切缘距离阈值比较了局部区域无瘤生存率(LRFS)、无病生存率(DFS)和总生存率(OS)。“肿瘤无墨水”切缘患者的5年LRFS为81.6%,切缘阳性患者为71.0%(p = 0.584)。切缘>1 mm与更好的预后相关,5年LRFS为84.0%,而切缘≤1 mm的患者为69.3%(p = 0.005)。此外,切缘>1 mm与更长的DFS(p = 0.028)和OS(p = 0.001)显著相关。这些发现表明,手术切缘距离>1 mm为这组BC患者提供了最佳的LRFS、DFS和OS结果。